BRIEF published on 10/29/2025 at 17:50, 10 months 13 days ago IntegraGen: Lower Results, Reduced Expenses in the First Half of 2025 Financial Results Treasury Cost Reduction Genomics CLIA/CAP Certification
PRESS RELEASE published on 10/29/2025 at 17:45, 10 months 13 days ago Informations privilégiées / Communiqué sur comptes, résultats IntegraGen annonce une baisse de 20% des charges d’exploitation et une trésorerie de 1,7 M€ au 30 juin 2025. L'accent est mis sur l'exécution opérationnelle et le développement des activités cliniques/pharma Développement Trésorerie IntegraGen Certification CLIA/CAP Baisses Charges
BRIEF published on 07/02/2025 at 07:35, 1 year 2 months ago IntegraGen signale une baisse de ses ventes et de ses réserves de trésorerie Baisse Des Ventes Coûts Opérationnels IntegraGen Besoins De Financement Analyses Génomiques
BRIEF published on 07/02/2025 at 07:35, 1 year 2 months ago IntegraGen Reports Decline in Sales and Cash Reserves Sales Decline Operational Costs IntegraGen Financing Needs Genomic Analyses
PRESS RELEASE published on 07/02/2025 at 07:30, 1 year 2 months ago Informations privilégiées / Autres communiqués Communiqué de presse: Chiffre d’affaires de 2,5 M€ et trésorerie de 2,1 M€ au premier semestre 2025 pour IntegraGen. Baisse des activités et exploration stratégique pour assurer la continuité des opérations Chiffre D'affaires Stratégie Baisse Trésorerie IntegraGen
PRESS RELEASE published on 07/02/2025 at 07:30, 1 year 2 months ago Inside Information / Other news releases IntegraGen reports sales of €2.5 million in the first half of 2025, a 31% decrease in sequencing activities at Évry and challenges with cash position leading to exploration of strategic options Sales Cash Position Strategic Options IntegraGen Decrease
BRIEF published on 01/15/2025 at 18:49, 1 year 7 months ago IntegraGen revenue down for 2024 Treasury Growth Turnover Genomics SeqOIA
BRIEF published on 01/15/2025 at 18:49, 1 year 7 months ago Chiffre d'affaires d'IntegraGen en baisse pour 2024 Chiffre D'affaires Croissance Trésorerie Génomique SeqOIA
PRESS RELEASE published on 01/15/2025 at 18:44, 1 year 7 months ago Inside Information / Information on annual revenues IntegraGen, an OncoDNA Group company, reports 27% revenue drop in 2024 due to SeqOIA services cessation. Cash position at €1.9m. Growth seen outside SeqOIA Cash Position Growth Prospects Revenue Drop SeqOIA IntegraGen
PRESS RELEASE published on 01/15/2025 at 18:44, 1 year 7 months ago Informations privilégiées / Information sur chiffre d’affaires annuel IntegraGen annonce un chiffre d'affaires annuel de 8,5 M€ pour 2024, en baisse de 27%, et une trésorerie de 1,9 M€. Perspectives de croissance positives malgré la baisse due à l'arrêt de SeqOIA Chiffre D'affaires Croissance Baisse Trésorerie IntegraGen
Published on 09/12/2026 at 02:35, 11 hours 6 minutes ago Gamma Resources Announces Extension of Private Placement Closing Date
Published on 09/11/2026 at 23:00, 14 hours 41 minutes ago Rio Grande Resources Engages Machai Capital for Investor Outreach
Published on 09/11/2026 at 22:05, 15 hours 36 minutes ago Usha Resources Announces Leadership Transition
Published on 09/11/2026 at 21:25, 16 hours 16 minutes ago Algo Grande Copper Intersects 30.23 Metres Grading 1.5% CuEq, including 3.55 Metres at 9.4% CuEq and 1.2-Metre Interval at 15.8% CuEq, 100 Metres Vertical Step-Out from Historical Intersects
Published on 09/11/2026 at 17:00, 20 hours 41 minutes ago Critical Elements Selected for Canada Investment Summit Prospectus, Showcasing Project to Leading Global Investors
Published on 09/12/2026 at 07:30, 6 hours 11 minutes ago NAGRAVISION Secures Formula 1 Content for RTL Croatia and PRO PLUS Slovenia
Published on 09/11/2026 at 22:15, 15 hours 26 minutes ago Amrize Appoints Mario Gross as President of Building Envelope
Published on 09/11/2026 at 22:10, 15 hours 31 minutes ago Quantinuum to Participate in the Piper Sandler 5th Annual Growth Frontiers Conference
Published on 09/11/2026 at 19:44, 17 hours 56 minutes ago DocMorris announces final conversion price and issue size of its New Convertible Bonds due 2031
Published on 09/11/2026 at 18:15, 19 hours 26 minutes ago CGTN: How BRICS creates new opportunities for Global South development
Published on 09/11/2026 at 07:00, 1 day 6 hours ago BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 1 day 6 hours ago BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Published on 09/10/2026 at 19:30, 1 day 18 hours ago Availability of the 2026 Interim Financial Report
